glp 1 agonists and sglt2 inhibitors combination The potential synergistic mechanisms of SGLT2i combined with GLP-1RAs Full article: Combination SGLT2 inhibitor
Description
For people with T2D, survodutide 1.8 mg twice weekly resulted in 9% WL vs
Research is ongoing to understand the full potential of side effects and implications of taking GLP-1 RAs in these particular populations
Of the 53 100 eligible for inclusion, 2003 were identified as GLP1 RA initiators, and 51 097 were identified as metformin users
Zhang J, et al
